Janux Therapeutics, Inc. Quarterly Debt-to-equity in % from Q1 2022 to Q2 2024

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Janux Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q1 2022 to Q2 2024.
Janux Therapeutics, Inc. Debt-to-equity for the quarter ending June 30, 2024 was 7.02 %, a 48.2% decline year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date
Q2 2024	7.02	-6.54	-48.2%	Jun 30, 2024
Q1 2024	9.05	-4.01	-30.7%	Mar 31, 2024
Q4 2023	12.1	+1.62	+15.5%	Dec 31, 2023
Q3 2023	12.9	+4.88	+61%	Sep 30, 2023
Q2 2023	13.6	+7.88	+139%	Jun 30, 2023
Q1 2023	13.1	+9.53	+270%	Mar 31, 2023
Q4 2022	10.5			Dec 31, 2022
Q3 2022	8			Sep 30, 2022
Q2 2022	5.68			Jun 30, 2022
Q1 2022	3.53			Mar 31, 2022

* An asterisk sign (*) next to the value indicates that the value is likely invalid.